Strategies for personalized precision immunotherapy.

Slides:

Advertisements

Similar presentations

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Advertisements

Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

Genome evolution within the individual

Big Data in Genomics, Diagnostics, and Precision Medicine

National Healthcare Science Week 2017

Figure 1 Overview of the IMPACT Analysis Pipeline

Socializing Individualized T-Cell Cancer Immunotherapy

High-Throughput Gene Expression and Mutation Profiling: Current Methods and Future Perspectives Breast Care 2013;8: DOI: / Fig.

Sarah Leary, MD MS CBTTC 5/25/2016

Immunotherapy for Lung Malignancies

Dose-escalation patient response.

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Clinical trial matching.

Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

West of England Genomics Medicine Centre Overview

PARPi combinations against HR-proficient tumors.

From Data to Therapies Research in Xinghua Lu’s Lab

A, baseline and 4-week PET scan from patient 2 (MET c

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer Takahiro Karasaki, MD, Kazuhiro Nagayama,

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

High throughput genome study to identify predictors of aggressiveness in patients with sporadic desmoid tumor who undergo a wait and see approach Chiara.

Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.

Potential clinical actionability.

Circulating tumor DNA: Solid data from liquid biopsies

Implementing Genome-Driven Oncology

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Clinical applications of CTC and ctDNA analyses in cancer care.

Neoantigen-specific TCR expansion in stimulated T-cell cultures.

Volume 155, Issue 6, Pages (December 2018)

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Jean-Emmanuel Bibault, Ingeborg Tinhofer

Chung-Han Lee, Roman Yelensky, Karin Jooss, Timothy A. Chan

Genomic Technologies and the New Era of Genomic Medicine

Fig. 1 Cancer exome–based identification of neoantigens.

Group 3 Group 3 The “Omes” Precision Cancer Medicine

Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment

Big science and big data in nephrology

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Presented by Nuraini Aguse

The Drosophila pipeline for modeling human disease.

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Elham Sherafat and Ion Mandoiu

Expression analysis of IGFBP-3 using human whole-genome microarray.

Integrative analysis of single-nucleus whole-genome sequencing and bulk tumor tissue enables detection of the subclonal architecture of tumors. Integrative.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Ablation of Nf1 in HOXB7 lineage cells gives rise to diffuse cNF.

HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Delineating cancer evolution with single-cell sequencing

Pros and cons for neoadjuvant immunotherapy.

Ten most frequent TCRs in the bulk 12TILs comprise >99% of the TIL population, and the neoantigens are shown to be the most dominant clones. Ten most frequent.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Enrichment of two rare SNPs among ABC DLBCL tumors.

Fig. 1 Cancer exome–based identification of neoantigens.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Genomic instability is a core feature of ovarian cancer that frequently involves DNA-damage repair genes. Genomic instability is a core feature of ovarian.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Vylyny Chat, Robert Ferguson, Tomas Kirchhoff

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Presentation transcript:

Strategies for personalized precision immunotherapy. Strategies for personalized precision immunotherapy. After biopsy of the patient's tumor, whole-exome sequencing permits characterization of the tumor genome and identification of predicted neoantigens. This patient-specific information can then be utilized to individualize immunotherapy care against tumor-specific vulnerabilities. Rajarsi Mandal, and Timothy A. Chan Cancer Discov 2016;6:703-713 ©2016 by American Association for Cancer Research